Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer
Erlotinib is approved for the treatment of non-small cell lung and pancreatic cancers, and is metabolized by CYP3A4. Inducers and inhibitors of CYP3A enzymes such as ritonavir and efavirenz, respectively, may be used as part of the highly active antiretroviral therapy drugs to treat patients with human immunodeficiency virus (HIV). When HIV patients with a malignancy need treatment with erlotinib, there is a potential of as-yet-undefined drug-drug interaction. We evaluated these interactions using human hepatocytes benchmarked against the interaction of erlotinib with ketoconazole and rifampin, the archetype cytochrome P450 inhibitor and inducer, respectively. Hepatocytes were treated with vehicle [0.1% dimethylsulfoxide, ritonavir (10 μM)], ketoconazole (10 μM), efavirenz (10 μM), or rifampin (10 μM) for 4 days. On day 5, erlotinib (5 μM) was incubated with the above agents for another 24-48 hours. Concentrations of erlotinib and O-desmethyl erlotinib were quantitated in collected samples (combined lysate and medium) using liquid chromatography and tandem mass spectrometry. The half-life (t(½)) of erlotinib increased from 10.6 ± 2.6 to 153 ± 80 and 23.9 ± 4.8 hours, respectively, upon treatment with ritonavir and ketoconazole. The apparent intrinsic clearance (C(Lint, app)) of erlotinib was lowered 16-fold by ritonavir and 1.9-fold by ketoconazole. Efavirenz and rifampin decreased t1/2 of erlotinib from 10.3 ± 1.1 to 5.0 ± 1.5 and 3.4 ± 0.2 hours, respectively. Efavirenz and rifampin increased the C(Lint, app) of erlotinib by 2.2- and 2-fold, respectively. Our results suggest that to achieve desired drug exposure, the clinically used dose (150 mg daily) of erlotinib may have to be significantly reduced (25 mg every other day) or increased (300 mg daily), respectively, when ritonavir or efavirenz is coadministered.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Drug metabolism and disposition: the biological fate of chemicals - 41(2013), 10 vom: 07. Okt., Seite 1843-51 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pillai, Venkateswaran C [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.04.2014 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1124/dmd.113.052100 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM22972034X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM22972034X | ||
003 | DE-627 | ||
005 | 20231224082753.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1124/dmd.113.052100 |2 doi | |
028 | 5 | 2 | |a pubmed24n0765.xml |
035 | |a (DE-627)NLM22972034X | ||
035 | |a (NLM)23913028 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pillai, Venkateswaran C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.04.2014 | ||
500 | |a Date Revised 21.10.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Erlotinib is approved for the treatment of non-small cell lung and pancreatic cancers, and is metabolized by CYP3A4. Inducers and inhibitors of CYP3A enzymes such as ritonavir and efavirenz, respectively, may be used as part of the highly active antiretroviral therapy drugs to treat patients with human immunodeficiency virus (HIV). When HIV patients with a malignancy need treatment with erlotinib, there is a potential of as-yet-undefined drug-drug interaction. We evaluated these interactions using human hepatocytes benchmarked against the interaction of erlotinib with ketoconazole and rifampin, the archetype cytochrome P450 inhibitor and inducer, respectively. Hepatocytes were treated with vehicle [0.1% dimethylsulfoxide, ritonavir (10 μM)], ketoconazole (10 μM), efavirenz (10 μM), or rifampin (10 μM) for 4 days. On day 5, erlotinib (5 μM) was incubated with the above agents for another 24-48 hours. Concentrations of erlotinib and O-desmethyl erlotinib were quantitated in collected samples (combined lysate and medium) using liquid chromatography and tandem mass spectrometry. The half-life (t(½)) of erlotinib increased from 10.6 ± 2.6 to 153 ± 80 and 23.9 ± 4.8 hours, respectively, upon treatment with ritonavir and ketoconazole. The apparent intrinsic clearance (C(Lint, app)) of erlotinib was lowered 16-fold by ritonavir and 1.9-fold by ketoconazole. Efavirenz and rifampin decreased t1/2 of erlotinib from 10.3 ± 1.1 to 5.0 ± 1.5 and 3.4 ± 0.2 hours, respectively. Efavirenz and rifampin increased the C(Lint, app) of erlotinib by 2.2- and 2-fold, respectively. Our results suggest that to achieve desired drug exposure, the clinically used dose (150 mg daily) of erlotinib may have to be significantly reduced (25 mg every other day) or increased (300 mg daily), respectively, when ritonavir or efavirenz is coadministered | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 7 | |a 14-alpha Demethylase Inhibitors |2 NLM | |
650 | 7 | |a Alkynes |2 NLM | |
650 | 7 | |a Anti-HIV Agents |2 NLM | |
650 | 7 | |a Benzoxazines |2 NLM | |
650 | 7 | |a Cyclopropanes |2 NLM | |
650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
650 | 7 | |a Nucleic Acid Synthesis Inhibitors |2 NLM | |
650 | 7 | |a Quinazolines |2 NLM | |
650 | 7 | |a Erlotinib Hydrochloride |2 NLM | |
650 | 7 | |a DA87705X9K |2 NLM | |
650 | 7 | |a efavirenz |2 NLM | |
650 | 7 | |a JE6H2O27P8 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Ketoconazole |2 NLM | |
650 | 7 | |a R9400W927I |2 NLM | |
650 | 7 | |a Rifampin |2 NLM | |
650 | 7 | |a VJT6J7R4TR |2 NLM | |
700 | 1 | |a Venkataramanan, Raman |e verfasserin |4 aut | |
700 | 1 | |a Parise, Robert A |e verfasserin |4 aut | |
700 | 1 | |a Christner, Susan M |e verfasserin |4 aut | |
700 | 1 | |a Gramignoli, Roberto |e verfasserin |4 aut | |
700 | 1 | |a Strom, Stephen C |e verfasserin |4 aut | |
700 | 1 | |a Rudek, Michelle A |e verfasserin |4 aut | |
700 | 1 | |a Beumer, Jan H |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug metabolism and disposition: the biological fate of chemicals |d 1990 |g 41(2013), 10 vom: 07. Okt., Seite 1843-51 |w (DE-627)NLM000015857 |x 1521-009X |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2013 |g number:10 |g day:07 |g month:10 |g pages:1843-51 |
856 | 4 | 0 | |u http://dx.doi.org/10.1124/dmd.113.052100 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2013 |e 10 |b 07 |c 10 |h 1843-51 |